ATOSSA THERAPEUTICS, INC.

For the period ended Mar 31, 2025. Filed May 13, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2025 · Filed May 13, 2025

ATOS$2.14+0.5%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Item 1. Condensed Consolidated Balance Sheets

CONDENSED CONSOLIDATED BALANCE SHEETS

(amounts in thousands, except share and per share data)

	March 31, 2025	December 31, 2024
Assets
Current assets
Cash and cash equivalents	$65,116	$71,084
Restricted cash	110	110
Prepaid materials	2,079	2,098
Prepaid expenses and other current assets	1,439	1,165
Total current assets	68,744	74,457
Other assets	2,003	1,987
Total assets	$70,747	$76,444
Liabilities and stockholders' equity
Current liabilities
Accounts payable	$1,165	$679
Accrued expenses	1,788	919
Payroll liabilities	942	1,862
Other current liabilities	1,530	1,507
Total current liabilities	5,425	4,967
Total liabilities	5,425	4,967
Commitments and contingencies (Note 12)	—	—
Stockholders' equity
Convertible preferred stock - $0.001 par value; 10,000,000 shares authorized; 582 shares issued and outstanding as of March 31, 2025 and December 31, 2024	—	—
Common stock - $0.18 par value; 350,000,000 shares authorized; 129,170,004 shares issued and outstanding as of March 31, 2025 and December 31, 2024	23,488	23,488
Additional paid-in capital	261,819	261,256
Treasury stock, at cost; 1,320,046 shares of common stock at March 31, 2025 and December 31, 2024	(1,475)	(1,475)
Accumulated deficit	(218,510)	(211,792)
Total stockholders' equity	65,322	71,477
Total liabilities and stockholders' equity	$70,747	$76,444

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.